Education
Finerenone in Cardio-Kidney-Metabolic Syndrome With Cancer History: FINE-HEART Insights
A large pooled post hoc analysis found that cancer history marked higher risk in cardio-kidney-metabolic syndrome, while finerenone benefits were consistent regardless of cancer history.
- Prepared by
- Iraq Cardiology Editorial Team
- Source authors
- Mihály Ruppert et al.
- Reading time
- 4 min
Quick summary
The essential point, in one sentence.
Reading companion
A professional question, bounded to this record.
Answers use this update and its recorded sources only; it does not provide individual treatment advice.
Ruppert and colleagues analysed participant-level data from the FINE-HEART pooled programme, combining FIDELIO-DKD, FIGARO-DKD, and FINEARTS-HF. Of 18,991 participants, 1,389 (7.3%) had a previous cancer diagnosis. A cancer history was associated with more advanced cardio-kidney-metabolic burden and higher risks of death and hospitalisation.
Across cancer-history subgroups, finerenone’s effects on the analysed clinical outcomes were reported as consistent. The pooled analysis found no evidence that a previous cancer diagnosis diminished the observed benefits on all-cause death, heart failure, hospitalisation, kidney outcomes, major adverse cardiovascular events, or new-onset atrial fibrillation.
The findings are reassuring within the trial populations, but they should not be read as cancer-treatment evidence or as a universal recommendation. This was a post hoc pooled analysis; cancer type, active malignancy, comedications, kidney function, potassium risk, and local prescribing guidance remain important in individual decisions.
Editorial note: Bayer AG is listed in the PubMed funding record. This professional summary is not patient-specific prescribing advice.
Professional discussion starter
Turn reading into a balanced conversation.
Prompts for professional reflection—not individual treatment advice.
- 1Which element of the source most changes how your team would frame Finerenone in Cardio-Kidney-Metabolic Syndrome With Cancer History: FINE-HEART Insights?
- 2Which limitation or context should be made explicit before discussing application?
- 3What question is worth taking to a journal club or multidisciplinary meeting?
Continue reading
Related updates
Education
Baghdad Teaching Hospital field record: a multidisciplinary Carvedilol teaching session
Dr. Farouq Hameed, Clinical Cardiology Fellow, led a Baghdad Teaching Hospital session on indication-specific Carvedilol use and clinical stability, supervised by Prof. Hasan Ali Farhan and attended by fellows across four cardiovascular disciplines.
Read updateEducation
HFpEF in 2026: diagnose the syndrome, search for mimics, treat the whole phenotype
A 2026 ACC expert pathway frames HFpEF as a multisystem syndrome: diagnose thoughtfully, look for cardiac and noncardiac mimics, and address comorbidities alongside evidence-based therapy.
Read update